AE Wealth Management LLC increased its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 16.9% during the 2nd quarter, HoldingsChannel reports. The fund owned 4,554 shares of the medical research company’s stock after purchasing an additional 660 shares during the quarter. AE Wealth Management LLC’s holdings in Amgen were worth $841,000 as of its most recent SEC filing.
A number of other large investors also recently made changes to their positions in AMGN. HC Financial Advisors Inc. purchased a new position in shares of Amgen during the fourth quarter valued at approximately $1,924,000. Boston Partners boosted its position in shares of Amgen by 7.5% during the first quarter. Boston Partners now owns 9,952 shares of the medical research company’s stock valued at $1,697,000 after buying an additional 698 shares during the last quarter. Financial Gravity Wealth Inc. purchased a new position in shares of Amgen during the first quarter valued at approximately $579,000. Frontier Investment Mgmt Co. boosted its position in shares of Amgen by 12.0% during the first quarter. Frontier Investment Mgmt Co. now owns 7,367 shares of the medical research company’s stock valued at $1,256,000 after buying an additional 790 shares during the last quarter. Finally, Grimes & Company Inc. boosted its position in shares of Amgen by 11.9% during the first quarter. Grimes & Company Inc. now owns 60,906 shares of the medical research company’s stock valued at $10,383,000 after buying an additional 6,483 shares during the last quarter. Hedge funds and other institutional investors own 77.20% of the company’s stock.
AMGN has been the topic of several analyst reports. Cann reaffirmed a “buy” rating and set a $224.00 target price on shares of Amgen in a research report on Monday, July 30th. BidaskClub raised Amgen from a “sell” rating to a “hold” rating in a research report on Friday, May 25th. Oppenheimer reaffirmed a “buy” rating and set a $224.00 target price on shares of Amgen in a research report on Tuesday, August 28th. Mizuho reissued a “buy” rating and issued a $200.00 price objective on shares of Amgen in a research report on Friday, July 27th. Finally, Goldman Sachs Group reissued a “buy” rating and issued a $228.00 price objective on shares of Amgen in a research report on Friday, July 27th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have given a buy rating to the stock. Amgen presently has an average rating of “Hold” and a consensus price target of $202.76.
Shares of AMGN opened at $200.58 on Friday. The firm has a market capitalization of $129.13 billion, a price-to-earnings ratio of 15.94, a PEG ratio of 1.94 and a beta of 1.39. The company has a debt-to-equity ratio of 2.03, a quick ratio of 3.12 and a current ratio of 3.39. Amgen, Inc. has a 1 year low of $163.31 and a 1 year high of $204.42.
Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, July 26th. The medical research company reported $3.83 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.52 by $0.31. The firm had revenue of $6.06 billion for the quarter, compared to analyst estimates of $5.73 billion. Amgen had a return on equity of 43.18% and a net margin of 10.19%. The business’s revenue was up 4.3% on a year-over-year basis. During the same period in the previous year, the company posted $3.27 earnings per share. research analysts anticipate that Amgen, Inc. will post 13.95 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Friday, September 7th. Shareholders of record on Friday, August 17th were paid a $1.32 dividend. The ex-dividend date was Thursday, August 16th. This represents a $5.28 annualized dividend and a dividend yield of 2.63%. Amgen’s payout ratio is presently 41.97%.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction on Monday, July 16th. The stock was sold at an average price of $195.71, for a total value of $298,457.75. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.19% of the company’s stock.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Further Reading: How is an ETF different from a mutual fund?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.